Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Claxton

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Nature|October 26, 2022
Subtype-specific 3D genome alteration in acute myeloid leukaemiaJie Xu, Fan Song, Huijue Lyu, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
Nature|October 26, 2022
Subtype-specific 3D genome alteration in acute myeloid leukaemiaJie Xu, Fan Song, Huijue Lyu, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Pageof 5